Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is the latest Big Pharma to sign an AI-biologics discovery deal, linking up with BioMap, a Beijing-based company built around a protein large language…
Sanofi has joined forces with Chinese AI biotech BioMap, paying $10 million upfront with the potential for more than $1 billion in milestones, to co-develop AI…
Sanofi has partnered with BioMap to develop artificial intelligence (AI) modules for accelerating biotherapeutic drug discovery, marking another pharma bet on…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi and BioMap entered a strategic collaboration to co-develop AI modules accelerating biotherapeutic drug discovery using BioMap's protein large language model. BioMap received $10M upfront plus near-term model development payments, with R&D/sales milestones across products totaling over $1B. Top-25 buyer inclusion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / BioMap Holdings Limited (this deal) | 2023 | $1.0B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Multiple (undisclosed) deals